Lumen is a small, dynamically typed programming language with its own interpreter, written from scratch in pure Python. It has variables, functions, recursion ...

The Trinity is a recursive self-improvement framework that couples world generation with agent Harness evolution. It organizes heterogeneous multimodal tasks by shared capability requirements and ...

Startup Recursive has released Flint, a free, laptop-sized coding model built largely by its own AI research system, as an early test of AI that improves itself.

For the past few days I’ve been testing an impressive open-weight AI coding model called Flint. It suggests that fully recursive self-improvement, or RSI—an exciting and controversial approach that ...

Solid-state battery specialist Factorial Energy is teaming up with Mitsui Kinzoku, one of the few companies producing sulfide-based solid electrolytes, to scale up the promising new technology.

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Regan Peng is an AI founder and former senior tech executive, focused on personal AI, ...

Factorial Funds, a venture firm launched five years ago by former Cruise engineer Sol Bier, has crossed $1 billion in realized profits, according to a letter the firm is sharing with its investors.

For years now Tim Holme has watched the same drama repeat itself roughly once a week. A headline arrives: some laboratory somewhere has cracked the problem, invented the battery of the future, solved ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...

The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.